| 臺大學術典藏 |
2022-09-08T07:35:35Z |
Fully digital problem-based learning for undergraduate medical students during the COVID-19 period: Practical considerations
|
Chao, Chia-Ter; Tsai, Chiao-Lin; Lin, Mong-Wei; Yang, Chih-Wei; CHAO-CHI HO; Chen, Huey-Ling; CHIUN HSU; Sheu, Bor-Ching |
| 臺大學術典藏 |
2022-09-08T07:29:51Z |
Effectiveness of tutor shadowing on faculty development in problem-based learning
|
Tsai, Chiao-Ling; Chiu, Yen-Lin; Chao, Chia-Ter; Lin, Mong-Wei; CHAO-CHI HO; Chen, Huey-Ling; Sheu, Bor-Ching; CHIUN HSU; Yang, Chih-Wei |
| 臺大學術典藏 |
2022-08-19T00:21:17Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Yeh K.-H.; Bu C.-F.; Lin C.-C.; Lu Y.-S.; Yang C.-H.; CHIUN HSU; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:17Z |
HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity
|
Cheng A.-L.; Wang S.-J.; Lee P.-H.; Huang C.-L.; Hsu H.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:21:16Z |
Survival-weighted health profile for long-term survivors of acute myelogenous leukemia
|
Tang J.-L.; Chen Y.-C.; Cheng A.-L.; Chang S.-M.; Tien H.-F.; Hwang J.-S.; Wang J.-D.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:21:16Z |
Using standardised measures of health-related quality of life: Critical issues for users and developers
|
Kind P.; CHIUN HSU; Wang J.-D.; Yao G.; Tang J.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:16Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma
|
Cheng A.-L.; Chang K.-J.; Chen M.M.; Lu Y.-S.; Bu C.-F.; CHIUN HSU; Huang C.-S.; Chao T.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:16Z |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma
|
CHIUN HSU; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Yang P.-M.; Lai M.-Y.; Lee P.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:15Z |
Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
|
Shen Y.-C.; CHIUN HSU; Chen J.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:15Z |
Recent advances in non-surgical treatment for advanced hepatocellular carcinoma
|
CHIUN HSU; Cheng J.C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:15Z |
Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13
|
Chie W.-C.; Yang C.-H.; CHIUN HSU; Yang P.-C. |
| 臺大學術典藏 |
2022-08-19T00:21:15Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.; Wu C.-Y.; Chen J.-S.; Li C.-C.; Liu H.-T.; Hsu C.-H.; Lu Y.-S.; Yeh K.-H.; Yang C.-H.; Shen Y.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:21:14Z |
Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: Implications from age-period-cohort analysis
|
Shen Y.-C.; Chang C.-J.; CHIUN HSU; Cheng C.-C.; Chiu C.-F.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:14Z |
Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors
|
CHIUN HSU; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Hsieh F.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:14Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
CHIUN HSU; Cheng A.-L.; Yang P.-C.; Yu C.-J.; Yang C.-H.; Kuo S.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:13Z |
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate
|
Lin C.-H.; Yen R.-F.; Jeng Y.-M.; Tzen C.-Y.; CHIUN HSU; Hong R.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:13Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Shih J.-Y.; CHIUN HSU; Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-08-19T00:21:12Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.; Cheng A.-L.; CHIUN HSU; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2022-08-19T00:21:12Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; CHIUN HSU; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2022-08-19T00:21:11Z |
CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma
|
Su M.-C.; CHIUN HSU; Kao H.-L.; Jeng Y.-M. |
| 臺大學術典藏 |
2022-08-19T00:21:10Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; CHIUN HSU; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:10Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Yang P.-C.; Chang G.-C.; CHIUN HSU; Gow C.-H.; Yang C.-H.; Shih J.-Y.; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P. |
| 臺大學術典藏 |
2022-08-19T00:21:10Z |
Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma
|
Chang Y.-T.; CHIUN HSU; Jeng Y.-M.; Chang M.-C.; Wei S.-C.; Wong J.-M. |
| 臺大學術典藏 |
2022-08-19T00:21:09Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Huang T.-C.; Ko B.-S.; Tang J.-L.; CHIUN HSU; Chen C.-Y.; Tsay W.; Huang S.-Y.; Yao M.; Chen Y.-C.; Shen M.-C.; Wang C.-H.; Tien H.-F. |
| 臺大學術典藏 |
2022-08-19T00:21:09Z |
Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: A preliminary result
|
Liang P.-C.; Ch'ang H.-J.; CHIUN HSU; Tseng S.S.; Shih T.T.F.; Wu Liu T. |
| 臺大學術典藏 |
2022-08-19T00:21:09Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.; Yeh K.-H.; Yang C.-H.; CHIUN HSU; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:08Z |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
|
Chen J.-P.; Lo Y.; Yu C.-J.; CHIUN HSU; Shih J.-Y.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:08Z |
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial
|
Cheng A.-L.; Chen P.-J.; Wu H.-B.; Tien H.-F.; Chao T.-Y.; Liu T.-W.; Li C.-C.; Liao Y.-M.; Chang M.-C.; Young J.-H.; Hsiao H.-H.; Lin T.-H.; Lin S.-F.; Wang M.-C.; Hwang W.-S.; Su I.-J.; CHIUN HSU; Hsiung C.A. |
| 臺大學術典藏 |
2022-08-19T00:21:08Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; CHIUN HSU; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
CHIUN HSU; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.; Chang M.-C.; Wei S.-C.; Tien Y.-W.; CHIUN HSU; Liang P.-C.; Tsao P.-N.; Jan I.-S.; Wong J.-M. |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Weekly cisplatin, infusional high-dose 5-fluorouracil and leucovorin for advanced, recurrent and metastatic cervical carcinoma
|
Hsiao S.-M.; Chen C.-A.; CHIUN HSU; Lin H.-H.; Hsieh C.-Y.; Wei L.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:06Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; CHIUN HSU; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:05Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; CHIUN HSU; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:05Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Cheng A.-L.; CHIUN HSU; Wang D.-S.; Lu Y.-S.; Fan H.-H.; Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:04Z |
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B
|
Liou J.-Y.; Shyue S.-K.; Chang C.-C.; Golubovskaya V.M.; Shen T.-L.; Shen Y.-C.; CHIUN HSU; Kuo C.-C.; Ko B.-S.; Chang T.-C.; Chen C.-H.; Liu C.-C. |
| 臺大學術典藏 |
2022-08-19T00:21:04Z |
Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design
|
CHIUN HSU; Shen Y.-C.; Cheng C.-C.; Hu F.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:04Z |
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma
|
Jan Y.-J.; Ko B.-S.; CHIUN HSU; Chang T.-C.; Chen S.-C.; Wang J.; Liou J.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:04Z |
Sorafenib for the treatment of hepatocellular carcinoma across geographic regions
|
CHIUN HSU; Shen Y.-C.; Cheng A.L. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
Chen P.-J.; Furuse J.; Han K.-H.; CHIUN HSU; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Cheng A.-L.; Ding Y.-H.; CHIUN HSU; Shao Y.-Y.; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:02Z |
Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma
|
Whang-Peng J.; Cheng A.-L.; CHIUN HSU; Chen C.-M. |
| 臺大學術典藏 |
2022-08-19T00:21:02Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Lin C.-H.; Chang K.-J.; Kuo W.-H.; CHIUN HSU; Lee W.-C.; Liau J.-Y.; Huang C.-S.; Lu Y.-S.; Shao Y.-Y.; Kuo K.-T.; Hu F.-C. |
| 臺大學術典藏 |
2022-08-19T00:21:01Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Shao Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:00Z |
Overexpression of 14-3-3�` predicts tumour metastasis and poor survival in hepatocellular carcinoma
|
Liou J.-Y.; Ko B.-S.; Chang T.-C.; CHIUN HSU; Chen Y.-C.; Shen T.-L.; Chen S.-C.; Wang J.; Wu K.K.; Jan Y.-J. |
| 臺大學術典藏 |
2022-08-19T00:21:00Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Chen B.-B.; Hsu C.-H.; Hu F.-C.; CHIUN HSU; Yu C.-W.; Shen Y.-C.; Hsu C.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:59Z |
Increased expression of 14-3-3�] promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma
|
Shen T.-L.; Lee Y.-M.; Chen P.-F.; Wang J.; Shyue S.-K.; Liou J.-Y.; CHIUN HSU; Liang S.-M.; Hung Y.-L.; Chen S.-C.; Jan Y.-J.; Ko B.-S.; Liu T.-A. |
| 臺大學術典藏 |
2022-08-19T00:20:59Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Lu Y.S.; Cheng A.L.; Kuo W.H.; Chen I.C.; Lin C.H.; Huang C.S.; Lien H.C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; CHIUN HSU; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:58Z |
Antiangiogenic strategies for the treatment of hepatocellular carcinoma
|
CHIUN HSU; Shen Y.-C.; Cheng A.-L. |
